Gamma-aminobutyric acid type A receptor (GABAA receptor) benzodiazepine-sensitive subtypes (GABAA receptor)

Gamma-aminobutyric acid type A (GABAA) receptors are pentameric ligand-gated ion channels that serve as the primary mediators of fast inhibitory neurotransmission in the mammalian central nervous system [1, 3]. The benzodiazepine-sensitive subtypes are specifically characterized by the inclusion of alpha1, alpha2, alpha3, or alpha5 subunits along with a gamma2 subunit, which together form a high-affinity allosteric binding site at the alpha/gamma interface [4, 6]. Upon binding, benzodiazepines act as positive allosteric modulators, increasing the frequency of chloride channel opening in response to GABA and leading to neuronal hyperpolarization [1, 12]. These receptors are essential for maintaining the balance between excitation and inhibition, and their dysfunction is implicated in disorders such as anxiety, epilepsy, and insomnia [7, 10]. Pharmacologically, different subunits are associated with distinct effects: alpha1 mediates sedation and anticonvulsant activity, while alpha2 and alpha3 are primarily responsible for anxiolysis and muscle relaxation [1, 12]. Clinically, drugs targeting these receptors, such as diazepam and zolpidem, are widely used but are associated with significant risks of tolerance, physical dependence, and cognitive impairment [15, 16]. Modern drug discovery efforts focus on developing subtype-selective ligands to isolate therapeutic benefits, such as treating pain or anxiety, without the sedative or addictive properties of traditional benzodiazepines [10, 12].

Other names

Benzodiazepine receptorBZD-sensitive GABAA receptorsIonotropic GABA receptorGABA(A) receptorGABAA receptor alpha1, alpha2, alpha3, alpha5 subtypes

Positive allosteric modulation (PAM) at the alpha/gamma subunit interface, increasing the frequency of chloride channel opening in the presence of GABA.